Active, not recruitingPhase 3NCT04526665
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ipsen
- Principal Investigator
- Ipsen Medical DirectorIpsen
- Intervention
- Elafibranor 80mg(drug)
- Enrollment
- 161 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2020 – 2028
Study locations (30)
- The Institute for Liver Health, Chandler, Arizona, United States
- Keck Medical Center of USC, Los Angeles, California, United States
- Ruane Clinical Research Group Inc., Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, Davis Medical Center, Sacramento, California, United States
- California Pacific Medical Center - Sutter Pacific Medical Foundation, San Francisco, California, United States
- University of Colorado Denver and Hospital, Aurora, Colorado, United States
- South Denver Gastroenterology, P.C., Englewood, Colorado, United States
- Yale School of Medicine, Digestive Diseases, New Haven, Connecticut, United States
- Encore Borland-Groover Clinical Research, Jacksonville, Florida, United States
- Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States
- Digestive Healthcare of Georgia, Atlanta, Georgia, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04526665 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta